Multiomic, plasma-only circulating tumor DNA (ctDNA) assay identifies breast cancer patients with minimal residual disease (MRD) and predicts distant recurrence

被引：0
|
作者：
Janni, Wolfgang [1 ]
Huober, Jens [1 ]
Braun, Tatjana [1 ]
Mueller, Volkmar [2 ]
Fink, Angelina [1 ]
de Gregorio, Amelie [1 ]
Rack, Brigitte [1 ]
Friedl, Thomas W. [1 ]
Wiesmueller, Lisa [1 ]
Pantel, Klaus [2 ]
Rich, Thereasa [3 ]
Parsana, Princy [3 ]
Zotenko, Elena [3 ]
Zhang, Shile [3 ]
Huesmann, Sophia [1 ]
机构：
[1] Univ Hosp Ulm, Ulm, Germany
[2] Univ Hosp Hamburg, Hamburg, Germany
[3] Guardant Hlth, Redwood City, CA USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3403
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Multiomic, plasma-only ctDNA NGS assay for minimal residual disease (MRD) detection in solid tumors.
    Kurata, Jessica
    Price, Kristin Sedgwick
    Banks, Kimberly
    Zotenko, Elena
    Hite, Dustin
    Cheng, Donavan
    Parsana, Princy
    Ju, Jin Hyun
    Dinman, Tara
    Miao, Zong
    Talasaz, AmirAli
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Minimal residual disease (MRD) detection in colorectal cancer (CRC) using a plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay
    Parikh, A.
    van Seventer, E.
    Boland, G.
    Siravegna, G.
    Hartwig, A.
    Jaimovich, A.
    Raymond, V. M.
    Talasaz, A.
    Corcoran, R. B.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S419 - S419
  • [3] Multiomic, Plasma-Only ctDNA NGS Assay Developed for Minimal Residual Disease (MRD) Detection in Early-Stage NSCLC
    Kurata, J.
    Price, K.
    Banks, K.
    Zotenko, E.
    Dinman, T.
    Parsana, P.
    Miao, Z.
    Ju, J.
    Hite, D.
    Cheng, D.
    Talasaz, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S952 - S953
  • [4] Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer
    Parikh, Aparna R.
    Van Seventer, Emily E.
    Siravegna, Giulia
    Hartwig, Anna, V
    Jaimovich, Ariel
    He, Yupeng
    Kanter, Katie
    Fish, Madeleine G.
    Fosbenner, Kathryn D.
    Miao, Benchun
    Phillips, Susannah
    Carmichael, John H.
    Sharma, Nihaarika
    Jarnagin, Joy
    Baiev, Islam
    Shah, Yojan S.
    Fetter, Isobel J.
    Shahzade, Heather A.
    Allen, Jill N.
    Blaszkowsky, Lawrence S.
    Clark, Jeffrey W.
    Dubois, Jon S.
    Franses, Joseph W.
    Giantonio, Bruce J.
    Goyal, Lipika
    Klempner, Samuel J.
    Nipp, Ryan D.
    Roeland, Eric J.
    Ryan, David P.
    Weekes, Colin D.
    Wo, Jennifer Y.
    Hong, Theodore S.
    Bordeianou, Liliana
    Ferrone, Cristina R.
    Qadan, Motaz
    Kunitake, Hiroko
    Berger, David
    Ricciardi, Rocco
    Cusack, James C.
    Raymond, Victoria M.
    Talasaz, AmirAli
    Boland, Genevieve M.
    Corcoran, Ryan B.
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (20) : 5586 - 5594
  • [5] Clinician utilization of a plasma-only, multiomic minimal residual disease (MRD) assay in 2,000 consecutive patients with colorectal cancer (CRC).
    Pedersen, Katrina Sophia
    Bucheit, Leslie A.
    Tan, Benjamin R.
    Hu, Zishuo Ian
    Shusterman, Michael
    Weipert, Caroline
    Banks, Kimberly
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15586 - E15586
  • [6] Postoperative minimal residual disease to predict the risk of hepatocellular carcinoma (HCC) recurrence using plasma-only circulating tumor DNA assay
    Pan, Mingxin
    Cai, Jianpeng
    Xu, Yuyan
    Zhong, Kaihang
    Chen, Tingting
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [7] Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
    Parikh, Aparna R.
    Chee, Bryant H.
    Tsai, Jill
    Rich, Thereasa A.
    Price, Kristin S.
    Patel, Sonia A.
    Zhang, Li
    Ibrahim, Faaiz
    Esquivel, Mikaela
    Van Seventer, Emily E.
    Jarnagin, Joy X.
    Raymond, Victoria M.
    Corvera, Carlos U.
    Hirose, Kenzo
    Nakakura, Eric K.
    Corcoran, Ryan B.
    Van Loon, Katherine
    Atreya, Chloe E.
    [J]. CLINICAL CANCER RESEARCH, 2024, 30 (14) : 2964 - 2973
  • [8] A plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay to inform recurrence risk in colorectal cancer (CRC).
    Parikh, Aparna Raj
    Van Seventer, Emily E.
    Boland, Genevieve Marie
    Hartwig, Anna
    Jaimovich, Ariel
    Raymond, Victoria M.
    Talasaz, AmirAli
    Corcoran, Ryan Bruce
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection
    Xu, Yuyan
    Cai, Jianpeng
    Zhong, Kaihang
    Wen, Yaohong
    Cai, Lei
    He, Guolin
    Liao, Hangyu
    Zhang, Cheng
    Fu, Shunjun
    Chen, Tingting
    Cai, Jinping
    Zhong, Xuefeng
    Chen, Chunzhu
    Huang, Mengli
    Cheng, Yuan
    Pan, Mingxin
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [10] Analysis of ctDNA for the detection of minimal residual disease (MRD) using a tissue-free, multiomic assay in patients with early-stage breast cancer
    Janni, Wolfgang
    Friedl, Thomas
    Rack, Brigitte
    Fasching, Peter A.
    Hartkopf, Andreas
    Tesch, Hans
    Lorenz, Ralf
    Heinrich, Georg
    Blohmer, Jens-Uwe
    Fehm, Tanja
    Mueller, Volkmar
    Schneeweiss, Andreas
    Beckmann, Matthias
    Ruebner, Matthias
    Harbeck, Nadia
    Pantel, Klaus
    Dustin, Derek
    Cai, Mingyang
    [J]. CANCER RESEARCH, 2024, 84 (09)
12345